Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zeneca launching Sular (nisoldipine) extended-release calcium channel blocker in January.

Executive Summary

ZENECA's SULAR (NISOLDIPINE) CCB WILL BE LAUNCHED IN JANUARY following a final agreement between Zeneca and Bayer AG giving Zeneca U.S. marketing and NDA rights to the once-daily calcium channel blocker. Zeneca is negotiating with Bayer for rights in other countries. Sular joins Zeneca's cardiovascular line of the ACE inhibitor Zestril (lisinopril), the ACE/diuretic combo Zestoretic, the beta-blocker Tenormin (atenolol), its diuretic combo Tenoretic and the nitrate Sorbitrate (isosorbide dinitrate).



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts